Name: Hovilpri (pritelivir) in Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults: Generic, brand name and therapeutic class of product
Published: 2026-10-11T11:04:25-04:00

Generic and brand name

“HOVILPRI (pritelivir) tablets, for oral use” (opens the prescribing information at this quote)
“HOVILPRI (hoe-vil-pree)” (opens the prescribing information at this quote)
“Active ingredient: pritelivir mesylate” (opens the prescribing information at this quote)

Field	Quoted record
Drug name	“Hovilpri”
Active ingredient	“pritelivir”

Brand name trademark

“HOVILPRI® is a registered trademark of Asahi Kasei Therapeutics, Inc. or its subsidiary” (opens the prescribing information at this quote)

Manufacturer: Asahi Kasei Therapeutics

“Distributed by: Asahi Kasei Therapeutics, Inc. Cary, North Carolina 27518” (opens the prescribing information at this quote)
“To report SUSPECTED ADVERSE REACTIONS, contact Asahi Kasei Therapeutics, Inc. at 1-844-835-6947 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.” (opens the prescribing information at this quote)

“HOVILPRI, a novel helicase-primase inhibitor, was developed by AiCuris Anti-infective Cures AG, which is now a part of Asahi Kasei Therapeutics.” (opens the source at this quote in a new tab)
“Asahi Kasei Therapeutics is the global specialty pharmaceutical business of Tokyo-based Asahi Kasei.” (opens the source at this quote in a new tab)

“The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with or without resistance (R±R), in immunocompromised patients” (opens the source at this quote in a new tab)

Corporate structure: Asahi Kasei Therapeutics brand

“Asahi Kasei announced that Asahi Kasei Therapeutics in Japan, Veloxis Pharmaceuticals in the United States, Calliditas Therapeutics in Sweden, and recently acquired AiCuris Anti-infective Cures in Germany will be brought together under the Asahi Kasei Therapeutics brand.” (opens the source at this quote in a new tab)
“This integration establishes a unified global management structure for Asahi Kasei’s pharmaceutical business.” (opens the source at this quote in a new tab)
“The 2026 acquisition of Aicuris further extended Asahi Kasei’s pipeline into infectious diseases and added further development capabilities in Europe.” (opens the source at this quote in a new tab)

“Aicuris is now part of Asahi Kasei Therapeutics. To learn more, visit:” (opens the source at this quote in a new tab)

Developer: AiCuris Anti-infective Cures AG

“Pritelivir, a novel helicase-primase inhibitor developed by Aicuris, targets both HSV-1 and HSV-2.” (opens the source at this quote in a new tab)

“AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases.” (opens the source at this quote in a new tab)

Field	Quoted record
Sponsor	“AiCuris Anti-infective Cures AG”
Other study ID numbers	“AIC316-03-E-01”

Development codes and nonproprietary name status

Field	Quoted record
Definition	“A thiazolylamide and helicase-primase enzyme inhibitor that is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2).”
Code name	“AIC-316”
Code name	“AIC316”
Code name	“BAY 57-1293”

“Aicuris published pharmacokinetic data for its lead candidate pritelivir (AIC316), an innovative therapeutic candidate targeting HSV replication, in May 2024.” (opens the source at this quote in a new tab)

Field	Quoted record
Name	“Pritelivir (USAN/INN)”
Formula	“C18H18N4O3S2”
Molecular weight	“402.50”

Therapeutic class: herpes simplex virus helicase-primase inhibitor

“HOVILPRI is a herpes simplex virus (HSV) helicase-primase inhibitor indicated in immunocompromised adults for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir.” (opens the prescribing information at this quote)
“HOVILPRI (pritelivir), a helicase-primase inhibitor, is developed as a mesylate monohydrate salt.” (opens the prescribing information at this quote)
“HOVILPRI is an antiviral drug against HSV-1 and HSV-2” (opens the prescribing information at this quote)
“Pritelivir is a HSV helicase-primase inhibitor.” (opens the prescribing information at this quote)

Therapeutic class: company description at approval

“HOVILPRI® (pritelivir), a novel oral helicase-primase inhibitor represents the first FDA approved HSV therapy with a novel mechanism of action in nearly 30 years.” (opens the source at this quote in a new tab)
“HOVILPRI is a helicase-primase inhibitor with a mechanism of action distinct from nucleoside analogue therapies.” (opens the source at this quote in a new tab)
“HOVILPRI is an orally administered HSV helicase-primase inhibitor indicated for the treatment of mucocutaneous lesions caused by HSV infection that is refractory, with or without documented resistance, to acyclovir, valacyclovir, or famciclovir in immunocompromised adults.” (opens the source at this quote in a new tab)

Chemical class: thiazolylamide

“Derived from a novel chemical class (thiazolylamides), pritelivir is active against both types of herpes simplex virus (HSV-1 and HSV-2), causing labial and genital herpes, and retains activity against viruses which have become resistant to marketed drugs.” (opens the source at this quote in a new tab)

Chemical description

“It is chemically described as Benzeneacetamide, N-[5-(aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl)-, methanesulfonate, hydrate (1:1:1).” (opens the prescribing information at this quote)
“Its molecular formula C19H22N4O6S3 x H2O corresponds to a molecular weight of 516.62 g/mole.” (opens the prescribing information at this quote)